1. Market Research
  2. > Healthcare
  3. > Health Facility Market Trends
  4. > EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

  • August 2016
  • -
  • GlobalData
  • -
  • 79 pages

Summary

Table of Contents

Search Inside

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Summary

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

- The Acute coronary syndrome (ACS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
- The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The ACS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global ACS market.
- Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 US Ancillary Hospital Locations (ER, OR, ICU, CCU) Diagnostics Market--Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

2017-2021 US Ancillary Hospital Locations (ER, OR, ICU, CCU) Diagnostics Market--Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

  • $ 7500
  • Industry report
  • February 2017
  • by Venture Planning Group

This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs).  The report includes analysis ...

2017-2021 US Critical Care Diagnostics Market in Ancillary Hospital Locations (ERs, ORs, ICU/CCUs): Test Volume and Sales Segment Forecasts, Supplier Shares, Competitive Strategies, Innovative Technologies, Instrumentation Review

2017-2021 US Critical Care Diagnostics Market in Ancillary Hospital Locations (ERs, ORs, ICU/CCUs): Test Volume and Sales Segment Forecasts, Supplier Shares, Competitive Strategies, Innovative Technologies, Instrumentation Review

  • $ 7500
  • Industry report
  • February 2017
  • by Venture Planning Group

This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs). The report includes analysis of ...

2017 US Hematology and Flow Cytometry Market: Hospitals, Commercial Laboratories, POC Locations

2017 US Hematology and Flow Cytometry Market: Hospitals, Commercial Laboratories, POC Locations

  • $ 7500
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500. Summary This comprehensive report contains 306 pages, 59 tables, and is designed to help current suppliers ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.